sur CROSSJECT (EPA:ALCJ)
Crossject: Details on Share Capital and Voting Rights as of November 30, 2024
Crossject, a specialty pharmaceutical company, has revealed the total number of voting rights and shares constituting its share capital as of November 30, 2024. In compliance with AMF regulations, the company is disclosing crucial information for its investors. The share capital is composed of 41,281,094 shares. This number is identical to that of the previous month, October 2024.
The total number of theoretical voting rights amounts to 51,059,559, while the exercisable voting rights are slightly lower, reaching 50,918,076. This difference is due to the shares deprived of voting rights, in particular those held by the company itself, amounting to 87,789, and those under liquidity contract, totaling 56,046. Thus, 143,835 shares do not have current voting rights.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CROSSJECT